Fatty acid-binding protein-4 (FABP4), commonly known as adipocyte-fatty acid-binding protein (A-FABP), is a pleiotropic adipokine that broadly affects immunity and metabolism. It has been increasingly recognized that FABP4 dysfunction is associated with various metabolic syndromes, including obesity, diabetes, cardiovascular diseases, and metabolic inflammation. However, its explicit roles within the context of women’s reproduction and pregnancy remain to be investigated. In this review, we collate recent studies probing the influence of FABP4 on female reproduction, pregnancy, and even fetal health. Elevated circulating FABP4 levels have been found to correlate with impaired reproductive function in women, such as polycystic ovary syndrome and endometriosis. Throughout pregnancy, FABP4 affects maternal–fetal interface homeostasis by affecting both glycolipid metabolism and immune tolerance, leading to adverse pregnancy outcomes, including miscarriage, gestational obesity, gestational diabetes, and preeclampsia. Moreover, maternal FABP4 levels exhibit a substantial linkage with the metabolic health of offspring. Herein, we discuss the emerging significance and potential application of FABP4 in reproduction and pregnancy health and delve into its underlying mechanism at molecular levels.

Review question / Objective: The Comparision of Impact of Chinese Medicine and Diane-35 on Sex Hormone Level in Adolescent with Polycystic Ovary Syndrome. Condition being studied: Adolescent patients who met the diagnostic criteria of PCOS. Information sources: English databases (PubMed, Embase, Web of Science, and the Cochrane Library) and Chinese databases (China National Knowledge Infrastructure(CNKI), Wanfang, the China Science and Technology Journal Database (VIP), and the Chinese Biomedical Literature Database (CBM)).

Review question / Objective: We conducted this systematic review and meta‐analysis to evaluate the morbidity of PCOS of GnRHa treatment in children with CPP in order to provide the reference of the long‐term safety of GnRHa therapy. Patient, Participant, or population: In the spectrum of CCP, patients presented thelarche, pubarche (TANNER score of at least 2 prior to the age of 8 years), or bone age advancement, and a serum LH concentration of 5 U/L after GnRH (or leuprolide) administration or a basal LH level of 0.3 U/L using ultra-sensitive assays.In the spectrum of PCOS, patients met the 2003 Rotterdam criteria.